Cardiff Oncology Inc (CRDF)

$1.68 -0.03 (-1.75%)
Market Cap 117.88M
Revenue (ttm) 680,000.00
Net Income (ttm) -45.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,680.88%
Debt to Equity Ratio 0.00
Volume 1,088,300
Avg Vol 1,341,942
Day's Range N/A - N/A
Shares Out 67.36M
Stochastic %K 7%
Beta 1.40
Analysts Strong Sell
Price Target $10.25

Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 952 7570
Address:
11055 Flintkote Avenue, San Diego, United States
biohuntress
biohuntress Feb. 4 at 3:09 AM
$CRDF CEO clearly stated "they are bringing in a new leadership team and expanded clinical team for mCRC late stage development and expansion into other indications...they are growing the company at large"....also "they are seeking a partner to develop those other indications"....under what scenario can that all be possible?.....is the company going to operate as a fully owned subsidiary that is only focused on developing multiple indications for Onva?.....CEO seems convinced they are not going away as a company......at the same time Cardiff employees being cut.....also the coy hesitancy when she said she could not talk about PFE at this time....WHAT'S UP?
0 · Reply
biohuntress
biohuntress Feb. 4 at 2:46 AM
$CRDF Mani https://www.roshontx.com/
1 · Reply
biohuntress
biohuntress Feb. 3 at 11:30 PM
$CRDF Alissa Sheldon Senior Clinical Trial Manager Cardiff Oncology · Full-time Cardiff Oncology · Full-time May 2022 - Dec 2025 · 3 yrs 8 mos ........looks like she is out also
1 · Reply
Lord_Andrew_London
Lord_Andrew_London Feb. 3 at 9:20 PM
$CRDF There Is not much to Say. 🤷
1 · Reply
BStrymon
BStrymon Feb. 3 at 9:19 PM
$CRDF buyout when?
1 · Reply
BubbaLubsGreen
BubbaLubsGreen Feb. 3 at 9:06 PM
I just noticed the February $5 calls for $CRDF . Wow.
1 · Reply
Vavavoom
Vavavoom Feb. 3 at 9:03 PM
$CRDF sigh to wake up one morning to BO news
1 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 7:57 PM
$CRDF they are happy for this shit price It is the reality
1 · Reply
_BUBBLES_
_BUBBLES_ Feb. 3 at 7:42 PM
$CRDF I refuse to believe that this isn’t an excellent buy🚀🚀🚀🚀
1 · Reply
Neba_
Neba_ Feb. 3 at 7:21 PM
$CRDF active dialogue with multiple large pharma as per Levine
2 · Reply
Latest News on CRDF
Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Jan 28, 2026, 6:23 AM EST - 6 days ago

Cardiff Oncology Stock Plunges After Sudden Leadership Change, Narrowed Trial Focus

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Jan 28, 2026, 2:12 AM EST - 6 days ago

Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC Transcript

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Jan 27, 2026, 7:05 AM EST - 7 days ago

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

Jan 27, 2026, 7:00 AM EST - 7 days ago

Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development

CTMX

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Jan 13, 2026, 10:48 AM EST - 21 days ago

Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Dec 8, 2025, 4:05 PM EST - 2 months ago

Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Dec 8, 2025, 7:00 AM EST - 2 months ago

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 24, 2025, 7:00 AM EST - 2 months ago

Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 3 months ago

Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 3 months ago

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology: Preparing For A Defining 2026

Oct 25, 2025, 7:50 AM EDT - 3 months ago

Cardiff Oncology: Preparing For A Defining 2026

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Oct 22, 2025, 7:45 AM EDT - 3 months ago

Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Aug 28, 2025, 4:05 PM EDT - 5 months ago

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Jul 30, 2025, 3:27 PM EDT - 6 months ago

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

Cardiff Oncology: Data Update Resolves Some Signals

Jul 30, 2025, 11:32 AM EDT - 6 months ago

Cardiff Oncology: Data Update Resolves Some Signals

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Jul 29, 2025, 4:07 PM EDT - 6 months ago

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Jun 27, 2025, 8:30 AM EDT - 7 months ago

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Cardiff Oncology Names Roger Sidhu as Medical Chief

Jun 17, 2025, 4:39 PM EDT - 8 months ago

Cardiff Oncology Names Roger Sidhu as Medical Chief

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Jun 17, 2025, 4:05 PM EDT - 8 months ago

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Jun 2, 2025, 4:05 PM EDT - 8 months ago

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

May 14, 2025, 9:05 AM EDT - 9 months ago

Cardiff Oncology: Buying The First-Line Onvansertib Strategy

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025, 4:05 PM EDT - 9 months ago

Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

May 2, 2025, 3:35 AM EDT - 9 months ago

Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Apr 23, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 15, 2025, 4:10 PM EDT - 10 months ago

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Apr 15, 2025, 4:05 PM EDT - 10 months ago

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:10 PM EST - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Feb 27, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Cardiff Oncology to Present at Upcoming Investor Conferences

Feb 24, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Feb 20, 2025, 4:05 PM EST - 1 year ago

Cardiff Oncology to Report Fourth Quarter 2024 Results and Provide Business Update

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Feb 18, 2025, 9:19 AM EST - 1 year ago

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

Dec 14, 2024, 9:00 AM EST - 1 year ago

Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone +

UI VOD DE ESPR FLNC GASS HII

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Dec 12, 2024, 5:38 AM EST - 1 year ago

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Dec 10, 2024, 5:05 PM EST - 1 year ago

Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Dec 10, 2024, 7:20 AM EST - 1 year ago

Cardiff Oncology Prices Oversubscribed $40 Million Underwritten Registered Direct Offering

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Dec 10, 2024, 6:00 AM EST - 1 year ago

Cardiff Oncology Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Oct 30, 2024, 4:30 PM EDT - 1 year ago

Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Oct 4, 2024, 1:10 PM EDT - 1 year ago

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Aug 12, 2024, 2:57 PM EDT - 1 year ago

Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 11:18 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript

Cardiff Oncology to Present at the Jefferies Healthcare Conference

May 29, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at the Jefferies Healthcare Conference

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

May 21, 2024, 11:22 PM EDT - 1 year ago

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data

Cardiff Oncology to Present at Upcoming Investor Conferences in May

May 13, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Present at Upcoming Investor Conferences in May

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

May 3, 2024, 1:30 AM EDT - 1 year ago

Cardiff Oncology, Inc. (CRDF) Q1 2023 Earnings Call Transcript

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

May 2, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Apr 25, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology to Report First Quarter 2024 Results and Provide Business Update

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Mar 8, 2024, 7:37 PM EST - 2 years ago

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Mar 6, 2024, 4:05 PM EST - 2 years ago

Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 8:06 PM EST - 2 years ago

Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript

biohuntress
biohuntress Feb. 4 at 3:09 AM
$CRDF CEO clearly stated "they are bringing in a new leadership team and expanded clinical team for mCRC late stage development and expansion into other indications...they are growing the company at large"....also "they are seeking a partner to develop those other indications"....under what scenario can that all be possible?.....is the company going to operate as a fully owned subsidiary that is only focused on developing multiple indications for Onva?.....CEO seems convinced they are not going away as a company......at the same time Cardiff employees being cut.....also the coy hesitancy when she said she could not talk about PFE at this time....WHAT'S UP?
0 · Reply
biohuntress
biohuntress Feb. 4 at 2:46 AM
$CRDF Mani https://www.roshontx.com/
1 · Reply
biohuntress
biohuntress Feb. 3 at 11:30 PM
$CRDF Alissa Sheldon Senior Clinical Trial Manager Cardiff Oncology · Full-time Cardiff Oncology · Full-time May 2022 - Dec 2025 · 3 yrs 8 mos ........looks like she is out also
1 · Reply
Lord_Andrew_London
Lord_Andrew_London Feb. 3 at 9:20 PM
$CRDF There Is not much to Say. 🤷
1 · Reply
BStrymon
BStrymon Feb. 3 at 9:19 PM
$CRDF buyout when?
1 · Reply
BubbaLubsGreen
BubbaLubsGreen Feb. 3 at 9:06 PM
I just noticed the February $5 calls for $CRDF . Wow.
1 · Reply
Vavavoom
Vavavoom Feb. 3 at 9:03 PM
$CRDF sigh to wake up one morning to BO news
1 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 7:57 PM
$CRDF they are happy for this shit price It is the reality
1 · Reply
_BUBBLES_
_BUBBLES_ Feb. 3 at 7:42 PM
$CRDF I refuse to believe that this isn’t an excellent buy🚀🚀🚀🚀
1 · Reply
Neba_
Neba_ Feb. 3 at 7:21 PM
$CRDF active dialogue with multiple large pharma as per Levine
2 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 7:17 PM
$BBNX it seems broke the timber resistance Watch $CRDF $$ABB
0 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 6:28 PM
$CRDF just an illusion ..all board must go out and change strategy …Starting a buy back
0 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 6:03 PM
$CRDF from timber day no rebound yet
0 · Reply
49829910w
49829910w Feb. 3 at 5:46 PM
$CRDF coding
0 · Reply
Messerschmittbf109
Messerschmittbf109 Feb. 3 at 5:30 PM
$CRDF CRDF: New CEO Presents Phase II Readout 03 Feb 2026
0 · Reply
Slowroast1
Slowroast1 Feb. 3 at 4:06 PM
$CRDF buy this
0 · Reply
jlwapw111
jlwapw111 Feb. 3 at 3:56 PM
$CRDF at this point arguing back and forth is not productive. Data drives outcome here.
0 · Reply
Blakeruss1
Blakeruss1 Feb. 3 at 3:53 PM
$CRDF green!!
0 · Reply
49829910w
49829910w Feb. 3 at 3:49 PM
$CRDF lol, and you are in the know? Oh yeaaaaa rigghhhhttt " MARK MY WORDS" been wrong every single post. Just stop and wake up that you are playing guess the narrative with your friend AI DD
1 · Reply
Andadiser
Andadiser Feb. 3 at 3:49 PM
$CRDF dont buy this …
1 · Reply
ZacksSCR
ZacksSCR Feb. 3 at 3:17 PM
$CRDF: New CEO Presents Phase II Readout https://buff.ly/GVtqytP
0 · Reply
User123321
User123321 Feb. 3 at 2:14 PM
$CRDF Yes and he uses some burner accounts to agree with himself and he just chided someone recently telling them they aren’t in the know implying he is. 😀 I’m sorry he doesn’t help the cause he hurts it. I’m not being mean. I’m just giving my opinion. Who do you serve with that carp 💩? You aren’t serving longs.
1 · Reply